These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37925660)

  • 1. Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials.
    Citera G; Jain R; Irazoque F; Madariaga H; Gruben D; Wang L; Stockert L; Santana K; Ebrahim A; Ponce de Leon D
    Rheumatol Ther; 2024 Feb; 11(1):35-50. PubMed ID: 37925660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.
    Wright GC; Mysler E; Kwok K; Cadatal MJ; Germino R; Yndestad A; Kinch CD; Ogdie A
    Rheumatol Ther; 2024 Jul; ():. PubMed ID: 38958913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis.
    Dougados M; Taylor PC; Bingham CO; Fallon L; Brault Y; Roychoudhury S; Wang L; Kessouri M
    RMD Open; 2022 Sep; 8(2):. PubMed ID: 36814062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib.
    Dikranian A; Gold D; Bessette L; Nash P; Azevedo VF; Wang L; Woolcott J; Shapiro AB; Szumski A; Fleishaker D; Wollenhaupt J
    Rheumatol Ther; 2022 Apr; 9(2):411-433. PubMed ID: 34921355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.
    Dikranian AH; Gonzalez-Gay MA; Wellborne F; Álvaro-Gracia JM; Takiya L; Stockert L; Paulissen J; Shi H; Tatulych S; Curtis JR
    RMD Open; 2022 May; 8(1):. PubMed ID: 35577477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
    Bartlett SJ; Bingham CO; van Vollenhoven R; Murray C; Gruben D; Gold DA; Cella D
    Arthritis Res Ther; 2022 Apr; 24(1):83. PubMed ID: 35382883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
    Bird P; Bensen W; El-Zorkany B; Kaine J; Manapat-Reyes BH; Pascual-Ramos V; Witcombe D; Soma K; Zhang R; Thirunavukkarasu K
    J Clin Rheumatol; 2019 Apr; 25(3):115-126. PubMed ID: 29794874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.
    Hall S; Nash P; Rischmueller M; Bossingham D; Bird P; Cook N; Witcombe D; Soma K; Kwok K; Thirunavukkarasu K
    Rheumatol Ther; 2018 Dec; 5(2):383-401. PubMed ID: 29949132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.
    Winthrop KL; Yndestad A; Henrohn D; Danese S; Marsal S; Galindo M; Woolcott JC; Jo H; Kwok K; Shapiro AB; Jones TV; Diehl A; Su C; Panés J; Cohen SB
    Rheumatol Ther; 2023 Apr; 10(2):357-373. PubMed ID: 36526796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials.
    Tesser J; Gül A; Olech E; Oelke K; Lukic T; Kwok K; Ebrahim A
    Arthritis Res Ther; 2023 Nov; 25(1):214. PubMed ID: 37919780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
    Strand V; van Vollenhoven RF; Lee EB; Fleischmann R; Zwillich SH; Gruben D; Koncz T; Wilkinson B; Wallenstein G
    Rheumatology (Oxford); 2016 Jun; 55(6):1031-41. PubMed ID: 26929445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fracture in clinical studies of tofacitinib in rheumatoid arthritis.
    Hansen KE; Mortezavi M; Nagy E; Wang C; Connell CA; Radi Z; Litman HJ; Adami G; Rossini M
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221142346. PubMed ID: 36601090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials.
    Bessette L; Mysler E; Kinch CD; Kwok K; Lukic T; On PV; van Vollenhoven RF
    J Rheumatol; 2022 Jun; 49(6):566-576. PubMed ID: 35232809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
    Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
    RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
    Li ZG; Liu Y; Xu HJ; Chen ZW; Bao CD; Gu JR; Zhao DB; An Y; Hwang LJ; Wang L; Kremer J; Wu QZ
    Chin Med J (Engl); 2018 Nov; 131(22):2683-2692. PubMed ID: 30425195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
    van Vollenhoven RF; Fleischmann R; Cohen S; Lee EB; García Meijide JA; Wagner S; Forejtova S; Zwillich SH; Gruben D; Koncz T; Wallenstein GV; Krishnaswami S; Bradley JD; Wilkinson B;
    N Engl J Med; 2012 Aug; 367(6):508-19. PubMed ID: 22873531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
    Strand V; Kaine J; Alten R; Wallenstein G; Diehl A; Shi H; Germino R; Murray CW
    Arthritis Res Ther; 2020 Oct; 22(1):243. PubMed ID: 33059710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment.
    Winthrop KL; Curtis JR; Yamaoka K; Lee EB; Hirose T; Rivas JL; Kwok K; Burmester GR
    Rheumatol Ther; 2022 Feb; 9(1):243-263. PubMed ID: 34870800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
    Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R
    Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.